|
|
|
|
In patients with symptomatic carotid stenosis, CAS is associated with a higher risk of stroke or death within 30 days of treatment than CEA. This extra risk is mostly attributed to an increase in periprocedural stroke occurring in patients �70 years. Beyond 30 days after treatment, CAS is as effective in preventing recurrent stroke as CEA. However, combining procedural safety and long-term efficacy in preventing recurrent stroke, CAS is still associated with higher risk than CEA. In people with asymptomatic carotid stenosis, there may be a small increase in the risk of stroke or death within 30 days of treatment with CAS compared with CEA. |
|